![]() |
市場調查報告書
商品編碼
1607750
定量吸入器的全球市場:產品·推進器·技術·適應症·流通管道·不同地區的預測 (~2032年)Global Metered Dose Inhalers Market Research Report Information By Product, By Propellant Type, By Technology, By Indication, By Distribution Channel And By Region Forecast Till 2032 |
2023 年和 2024 年全球計量吸入器市場規模預計為 158 億美元 6 預測期間同期,2019 年為171 億美元。預計複合年增長率為 43%,到 2032 年將達到 300 億美元。由於呼吸系統疾病盛行率的增加、新產品的推出以及公眾意識和教育的提高,全球計量吸入器市場正在成長。
由於新產品的可用性不斷擴大,全球計量吸入器市場正在經歷顯著成長。這些產品的推出帶來的技術進步,例如改進的給藥系統和人體工學設計,符合患者對易用性和用藥依從性的需求。創新的配方和組合為多種呼吸系統疾病提供了新的治療選擇,提高了治療效果和患者治療結果的品質。
區域展望
北美預計將在 2023 年擁有最大的市場佔有率,而亞太地區預計在預測期內呈現最高的複合年增長率。 北美計量吸入器市場的特點是支持性的監管環境、技術進步和不斷增長的醫療保健要求,所有這些都推動了強勁的成長。此外,尖端計量吸入器的發展推動了該區域市場的發展,而這得益於對研發和先進醫療基礎設施的大量投資。
歐洲計量吸入器市場的特點是醫療基礎設施完善和醫療支出不斷增長。
在預測期內,亞太地區預計將在多種因素的推動下實現強勁發展。預計它也將成為成長最快的地區。中國、印度和日本等國家醫療保健基礎設施的快速擴張和醫療保健基礎設施投資的增加推動了對先進吸入器的需求。
本報告提供全球定量吸入器的市場調查,市場定義和概要,市場成長的各種影響因素分析,市場規模的轉變·預測,各種區分·地區/各主要國家的明細,競爭環境,主要企業簡介等資訊。
Global Metered Dose Inhalers Market Research Report Information By Product (Press Metered Dose Inhalers, Breath Actuated Metered Dose Inhalers), By Propellant Type (HFA 134A, HFA 227EA, HFA 152A), By Technology (Pulmonary Platform Technologies, Nasal Platform Technologies), By Indication (Asthma, COPD, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) Forecast Till 2032
In 2023, the Metered Dose Inhalers Market was estimated to be worth USD 15.8 billion. Over the forecast period (2024-2032), the industry is anticipated to expand from USD 17.1 billion in 2024 to USD 30.0 billion by 2032, with a compound annual growth rate (CAGR) of 6.43%. The global metered-dose inhaler market is experiencing development due to the increasing prevalence of respiratory diseases, the launch of new products by market players, and the increasing awareness and education of the public.
The global MDI market is experiencing significant growth due to the increasing availability of new metered dose inhaler (MDI) products. The technological advancements that these launches bring about, such as improved drug delivery systems and ergonomic designs, are tailored to the preferences of patients for simplicity of use and adherence. Innovative formulations and combinations provide additional therapeutic options for a diverse array of respiratory conditions, thereby enhancing the efficacy of treatment and the quality of patient outcomes.
Market segment insights
The Metered Dose Inhalers Market has been segmented into Press Metered Dose Inhalers and Breath actuated Metered Dose Inhalers based on product.
The Metered Dose Inhalers Market has been segmented into HFA 134a, HFA 227ea, and HFA-152a based on propellant type.
The Metered Dose Inhalers Market has been segmented into pulmonary platform technologies and nasal platform technologies based on technology.
Metered Dose Inhalers Market has been segmented into Asthma, COPD, and other categories based on indication.
Hospital pharmacies, retail pharmacies, and online pharmacies comprise the Metered Dose Inhalers Market, contingent upon their distribution channels.
Regional Perspectives
In 2023, the market share that North America possessed was the most significant. Nevertheless, Asia-Pacific is anticipated to experience the most significant compound annual growth rate (CAGR) during the 2024-2032 forecast period.
The Metered Dose Inhalers market in North America is distinguished by a supportive regulatory environment, technological advancements, and increased healthcare requirements, all of which are driving robust growth. Additionally, the market is driven by the development of state-of-the-art Metered Dose Inhalers, which is made possible by a substantial investment in research and development and a sophisticated healthcare infrastructure.
Europe, which is further divided into Germany, France, the United Kingdom, Italy, Spain, and the Rest of Europe, follows the Americas region. The Metered Dose Inhalers market in Europe is characterized by a well-established healthcare infrastructure and an increase in healthcare expenditure.
Over the forecast period, the Asia-Pacific region is anticipated to experience robust development, which is driven by a variety of key factors. It is also projected to be the fastest-growing region. The demand for sophisticated inhalers is being driven by the rapid expansion of healthcare infrastructure and the increasing investments in healthcare infrastructure in countries such as China, India, and Japan.
AstraZeneca (UK), GSK PLC. (UK), Organon (US), Cipla, Inc. (India), Lupin Pharmaceuticals, Inc. (India), Zydus Group (India), Teva Pharmaceutical Industries Ltd. (Israel), Viatris Inc. (US), Aristopharma Ltd. (Bangladesh), and Beximco Pharmaceuticals Limited (Bangladesh) are among the key companies in the Metered Dose Inhalers Market.
SOURCE: ANNUAL REPORT AND PRESS RELEASES